Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387025 | 0.87 | SCN4A (0.40) | MGLLGAA | |
| SCHEMBL5376216 | 0.76 | NPC1 (0.52) | DAGLAMGLLTRPV1 | |
| SCHEMBL5371714 | 0.72 | DPP4 (0.39) | DAGLAPHGDHGAA | |
| SCHEMBL9550296 | 0.72 | ALDH1A1 (0.49) | MGLLP2RX4GAA | |
| SCHEMBL2179538 | 0.71 | BCHE (0.48) | DAGLABCHEACHELIPEMGLL | |
| SCHEMBL5371737 | 0.70 | LMNA (0.52) | GAAHTT | |
| SCHEMBL9851965 | 0.70 | TSHR (0.44) | GAA | |
| SCHEMBL5376606 | 0.69 | KMT2A (0.42) | GAAHTT | |
| SCHEMBL5381803 | 0.67 | RORC (0.38) | BCHEACHELIPEMGLLTRPV1 | |
| SCHEMBL5374063 | 0.66 | DPP4 (0.36) | MGLLTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258480-A1 | Pharmaceutical use of N-Carbamoylazole derivatives | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | DAGLA 1213/4885NPY5R 1028/4885BCHE 115/4885 |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | DAGLA 1213/4885NPY5R 1028/4885BCHE 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.